Psoriasis Prime Time 1

The Role of TYK Inhibition of Psoriasis

References

- Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. *Clin Exp Rheumatol*. 2015;33(5 Suppl 93):S2-S6.
- Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. *JAMA*. 2020;323(19):1945-1960.
- Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. *J Am Acad Dermatol*. 2023;88(1):29-39.
- Armstrong AW, Lebwohl M, Warren, RB, et al. Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials. *SKIN J Cutan Med.* 2023;7(6):s240.
- Armstrong AW, Park SH, Patel V, et al. Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis [published correction appears in Dermatol Ther (Heidelb). 2023 Oct 18;:]. *Dermatol Ther (Heidelb)*. 2023;13(11):2589-2603.
- Armstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: A network meta-analysis. *Dermatol Ther (Heidelb)*. 2023;13(11):2839-2857.
- Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?. *Ann Rheum Dis*. 2018;77(2):175-187.
- Choy EH. Clinical significance of Janus Kinase inhibitor selectivity [published correction appears in Rheumatology (Oxford). 2019 Jun 1;58(6):1122]. *Rheumatology (Oxford)*. 2019;58(6):953-962.
- Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: Immunobiology and pathology. *Annu Rev Immunol*. 2015;33:747-85.
- Gooderham M, Spelman L, Imafuku S, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: Efficacy by baseline demographic and disease characteristics in the phase 3 POETYK PSO-1 and PSO-2 trials. Presented at: 2023 EADV Symposium; 5/18/23-5-20/23; Seville, Spain. ABST 985.
- Gooderham M, Spelman L, Imafuku S, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: Efficacy by baseline demographic and disease characteristics in the phase 3 POETYK PSO-1 and PSO-2 trials Presented at: Fall Clinical Dermatology Conference for PAs & NPs; 6/9/23-6/11/23; Orlando, FL

- Imafuku S, Okubo Y, Tada Y, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque psoriasis: laboratory parameters in the phase 3 POETYK PSO-4 trial. Presented at: EADV Congress; 10/11/23-10/14/23; Berlin, Germany. Abst 1970.
- Korman NJ, Papp K, Bagel J, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: Onset of action in the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. Presented at: Fall Clinical Dermatology Conference; 10/21/21-10/24/21; Las Vegas, NV.
- Lebwohl M, Warren RB, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. *Br J Dermatol*. 2024;190(5):668-679.
- Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R. TYK2: an emerging therapeutic target in rheumatic disease. *Nat Rev Rheumatol*. 2024;20(4):232-240.
- Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. *Br J Dermatol*. 2015;173(4):949-961.
- Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. *Br J Dermatol*. 2016;174(6):1266-1276.
- Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. *Br J Dermatol*. 2018;179(1):54-62.
- Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nat Rev Rheumatol*. 2016;12(1):25-36.
- Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. *J Am Acad Dermatol*. 2023;88(1):40-51.
- Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: Discovery of the allosteric inhibitor BMS-986165. *J Med Chem*. 2019;62(20):8973-8995.
- Zhang J, Ding Y, Wang P, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: onset of action and maintenance of response in the phase 3 POETYK PSO-3 trial. Presented at: 32ND EADV Congress; 10/11/23-10/14/23; Berlin Germany. Abst 2564.